Comparative Pharmacology
Head-to-head clinical analysis: BINIMETINIB versus TRAMETINIB DIMETHYL SULFOXIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BINIMETINIB versus TRAMETINIB DIMETHYL SULFOXIDE.
BINIMETINIB vs TRAMETINIB DIMETHYL SULFOXIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binimetinib is a reversible, non-ATP-competitive allosteric inhibitor of MEK1 and MEK2, blocking downstream ERK phosphorylation and signaling in the RAS-RAF-MEK-ERK pathway.
Trametinib is a reversible, selective inhibitor of MEK1 and MEK2, downstream effectors of the RAS/RAF/MEK/ERK signaling pathway, thereby inhibiting cell proliferation.
45 mg orally twice daily.
2 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 3.5–4 hours at steady state; no significant accumulation observed with twice-daily dosing.
Terminal elimination half-life approximately 5.3 days (127 hours); supports once-daily dosing with steady-state achieved in ~21 days.
Primarily hepatic metabolism with biliary-fecal elimination; unchanged drug in urine is negligible (<1%). In mass balance studies, ~70-80% of the dose is recovered in feces (mainly as metabolites) and <20% in urine (as metabolites).
Primarily fecal (80%), with 20% excreted in urine; less than 0.1% recovered unchanged in urine.
Category C
Category C
MEK Inhibitor
MEK Inhibitor